All In Biotech

Drug Trial Radar · NCT05905458

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Last checked: Nov 19, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Jul 28, 2023

Primary completion

Nov 22, 2024

Study completion Nov 22, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).

Conditions

  • Chronic Hepatitis B

Interventions

  • HRS9950 tabletsDrug

    HRS9950 tablets, oral, once a week, low dose

  • HRS9950 tabletsDrug

    HRS9950 tablets, oral, once a week, high dose

  • HRS9950 placebo tabletsDrug

    HRS9950 placebo tablets, oral, once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mean log10 serum hepatitis B surface antigen levels from baseline to week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.